presentation mode
Loading

Vanderbilt Infant Health Technologies

Caring for our youngest.

Wellness

Safety

Diagnostic

Premature Birth

Identifying Causes of Disease

Software

Introducing 9 promising new technologies.

Personalized health coaching for families, emphasizing family health. Available in Spanish.

GROW Healthier

Prognostic test that measures genetic and environmental factors that indicate high-risk for severe Respiratory Syncytial Virus (RSV) infection.

Electronic pediatric growth chart.

Pediatric Growth Chart

A mobile-enabled device for accurate identification and monitoring of malnourished individuals in remote locations.

Malnutrition Screening Device

A car seat safety attachment that detects if a child has been left unattended in a car seat and if the environment has become uncomfortably hot or cold. The system is designed with a graduated alarm system based on "alert states" that provides a combination of visual, tactile and audio alerts.”

KidSense Car Seat Safety System

Data bank of linked genetic, diagnostic, therapeutic and pharmacological information that can be mined to identify the genetic and phenotypic cause of disease, clinical biomarkers and adverse drug events. BioVU currently has tens of thousands of pediatric samples and continues to expand.

Diagnostic test that measures premature birth risk prior to conception.

Most electronic medical records are started at birth. This tool captures critical medical information prior to birth to extend the child's medical history.

Mobile app for parents to easily monitor the growth of premature infants in the NICU and beyond.

An estimated 15 million babies are born prematurely each year, with 1 of 9 babies in the U.S. coming too soon.

Vanderbilt currently has two technologies directly related to the care of premature infants: - Premature Birth Prediction Diagnostic - Growth Chart for Preemies

BioVU is a unique resource built by Vanderbilt University Medical Center that provides a "view into biology" at the level of DNA and is the essence of personalized medicine. BioVU is a patient DNA bank with linked de‐identified patient records. These records include diagnosis, administered therapies, and outcomes. The power of this asset is the linkage of biological samples to its corresponding de‐identified patient data, which allows for retrospective and prospective analysis of biology‐phenotype linkages for a medical condition or therapy.

BioVU: A DNA Data Bank

200,000 DNA samples

samples added per week

700

samples are currently undergoing genotyping

50,000

Produced by Vanderbilt CTTC